Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Age
18–55
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Has body mass index (BMI) ≥18.5 and ≤32.0 kg/m\^2
Is in good health
You may not be if
Has history or presence of any medical condition or prior surgery that may impact typical absorption, distribution, metabolism, or excretion of the orally administered study drug (e.g., gastric bypass, gastrointestinal dysmotility, irritable or inflammatory bowel disease)
Has history or laboratory evidence of hyperthyroidism (thyroid-stimulating hormone \[TSH\] \< lower limit of normal \[LLN\]) or hypothyroidism (TSH ≥8 mIU/L)
Has history of cancer that has not been in complete remission for \> 5 years (except basal cell skin cancer or squamous cell skin cancer with a history of curative treatment and no recurrence for \> 1 year prior)
Has history of dysphagia, aspiration, or other conditions that could potentially impede the ability to safely orally ingest the study drug per protocol
Has history of incomplete bladder emptying with voiding (i.e., urinary retention) or recent history of awakening more than once at night to void
Has usual habit of \< 1 or \> 3 bowel movements per day
Has family history of long QT syndrome or of unexplained sudden death in a first-degree relative under 50 years of age
Has documented congenital or acquired long QT syndrome
Clareo Health | A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)
